An Open-Label, Parallel-Group, Multi-Center Phase I Study to Investigate the Pharmacokinetics of NKTR-102 for Injection (Etirinotecan Pegol) in Patients with Advanced or Metastatic Solid Tumors and Mild or Moderate Hepatic Impairment.
Phase of Trial: Phase I
Latest Information Update: 10 Oct 2017
Price : $35 *
At a glance
- Drugs Etirinotecan pegol (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Nektar Therapeutics
- 05 Oct 2017 Status changed from active, no longer recruiting to completed.
- 08 Aug 2017 Planned End Date changed from 1 Dec 2017 to 1 Sep 2017.
- 08 Aug 2017 Status changed from recruiting to active, no longer recruiting.